An Open-Label, Multicenter, Phase IB/II Clinical Study of HRS-7172 in Combination With Antitumor Therapy in Participants With Solid Tumors

This is a Phase IB/II clinical trial designed to evaluate HRS-7172 in combination with antitumor drugs in participants with advanced pancreatic cancer harboring RAS mutations or amplifications. The study process includes a screening period (from signed informed consent to first dose), a treatment period (from first dose to last dose), and a follow-up period (safety and survival follow-up after last dose). A Safety Monitoring Committee (SMC), composed of the principal investigator and sponsor representatives, will be established during the study to review the safety and efficacy data generated

Trial Details

NCT ID
NCT07806058
Phase
PHASE1 / PHASE2
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • HRS-7172 + AG + SHR-1316
  • HRS-7172 + AG + SHR-1316;
  • HRS-7172 + AG;
  • HRS-717 + HRS-4642+SHR-1316;
  • HRS-717 + HRS-4642;
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Capable of giving informed consent, have signed and dated the IRB/EC-approved informed consent form, and are willing and able to comply with schedu…
  • Aged 18 to 70 years (inclusive) at the time of signing the informed consent form, regardless of sex.
  • ECOG performance status of 0 or 1.
  • Locally advanced or metastatic pancreatic cancer confirmed by histology and cytology, with RAS mutation/amplification detected by tissue or blood g…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →